Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.

[1]  Jörg Menche,et al.  Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. , 2019, Molecular cell.

[2]  Matthew C. Canver,et al.  CRISPResso2 provides accurate and rapid genome editing sequence analysis , 2019, Nature Biotechnology.

[3]  B. Ebert,et al.  Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. , 2018, Blood.

[4]  Ling-Zhi Wang,et al.  Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma , 2018, Proceedings of the National Academy of Sciences.

[5]  James E. Bradner,et al.  The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.

[6]  M. Naito,et al.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation , 2018, The Journal of Biological Chemistry.

[7]  V. Baladandayuthapani,et al.  Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma , 2018, Leukemia.

[8]  M. Wang,et al.  BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells , 2018, Leukemia.

[9]  Christopher J. Ott,et al.  Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands , 2018, Nature Chemical Biology.

[10]  D. Auclair,et al.  Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders , 2018, British journal of haematology.

[11]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[12]  C. Crews,et al.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.

[13]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[14]  T. Heightman,et al.  Protein degradation: a validated therapeutic strategy with exciting prospects. , 2017, Essays in biochemistry.

[15]  Y. Asmann,et al.  High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma , 2017, Blood Cancer Journal.

[16]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[17]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[18]  Sandeep Rana,et al.  Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). , 2017, Chemical communications.

[19]  Margaret A. Goralski,et al.  Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 , 2017, Science.

[20]  T. Owa,et al.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides. , 2017, Nature chemical biology.

[21]  J. Ovádi,et al.  Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). , 2017, Journal of medicinal chemistry.

[22]  J. McCarter,et al.  A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. , 2017, Journal of medicinal chemistry.

[23]  Tudor I. Oprea.  Faculty Opinions recommendation of Structural basis of PROTAC cooperative recognition for selective protein degradation. , 2017 .

[24]  Liu Liu,et al.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression , 2017, Journal of medicinal chemistry.

[25]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[26]  S. Armstrong,et al.  ENL links histone acetylation to oncogenic gene expression in AML , 2017, Nature.

[27]  John G Doench,et al.  ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. , 2017, Cell reports.

[28]  P. Qiu,et al.  Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells , 2016, Leukemia.

[29]  T. Heightman,et al.  Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras , 2016, ACS central science.

[30]  T. Pisitkun,et al.  Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation. , 2016, Physiological genomics.

[31]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[32]  K. Robert Lai,et al.  UbiNet: an online resource for exploring the functional associations and regulatory networks of protein ubiquitylation , 2016, Database J. Biol. Databases Curation.

[33]  M. Cole.  Faculty Opinions recommendation of DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. , 2016 .

[34]  Jeanne Kowalski,et al.  Gene integrated set profile analysis: a context-based approach for inferring biological endpoints , 2016, Nucleic acids research.

[35]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[36]  J. Zuber,et al.  Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. , 2015, Blood.

[37]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[39]  I. E. Smith,et al.  HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. , 2015, ACS chemical biology.

[40]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[41]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[42]  A. Ciulli,et al.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.

[43]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[44]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[45]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[46]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[47]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[48]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[49]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[50]  R. Chopra,et al.  Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity , 2013, British journal of haematology.

[51]  Jessica E. Bolden,et al.  Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities , 2013, Molecular Cancer Therapeutics.

[52]  U. Jäger,et al.  High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone , 2013, British journal of haematology.

[53]  Yuan-Xiao Zhu,et al.  Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma , 2013, Leukemia & lymphoma.

[54]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[55]  K. Anderson,et al.  Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. , 2012, Blood.

[56]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[57]  W. Rathmell,et al.  Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. , 2012, Molecular cell.

[58]  D. McMillin,et al.  Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma , 2012, Molecular Cancer Therapeutics.

[59]  K. Sugasawa,et al.  The Molecular Basis of CRL4DDB2/CSA Ubiquitin Ligase Architecture, Targeting, and Activation , 2011, Cell.

[60]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[61]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[62]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[63]  K. Anderson,et al.  Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation , 2011, PloS one.

[64]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[65]  S. Welford,et al.  Renal Oxygenation Suppresses VHL Loss-Induced Senescence That Is Caused by Increased Sensitivity to Oxidative Stress , 2010, Molecular and Cellular Biology.

[66]  K. Anderson,et al.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.

[67]  W. Dubiel.  Resolving the CSN and CAND1 paradoxes. , 2009, Molecular cell.

[68]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[69]  N. Munshi,et al.  Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. , 2008, Cancer research.

[70]  J. Callis,et al.  Regulation of cullin RING ligases. , 2008, Annual review of plant biology.

[71]  S. Signoretti,et al.  VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.

[72]  S. Elledge,et al.  The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression , 2005, Nature.

[73]  Richard D Klausner,et al.  VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. , 2002, Cancer research.

[74]  P. Raychaudhuri,et al.  Cullin 4A Associates with the UV-damaged DNA-binding Protein DDB* , 1999, The Journal of Biological Chemistry.

[75]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.

[76]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.